Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31201837 | 1.00 | CRBN (0.57) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL23861070 | 1.00 | CRBN (0.57) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL30133330 | 0.88 | CRBN (0.53) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL23860985 | 0.88 | CRBN (0.67) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL30133255 | 0.88 | CRBN (0.53) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL23860850 | 0.88 | CRBN (0.53) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL23860792 | 0.88 | CRBN (0.53) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL30133249 | 0.88 | CRBN (0.67) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL23860878 | 0.88 | CRBN (0.55) | CRBNIKZF1CSNK1A1IKZF2 | |
| SCHEMBL23860886 | 0.88 | CRBN (0.55) | CRBNIKZF1CSNK1A1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | claimed |
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | claimed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | claimed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | CRBN 3187/4885IKZF1 3208/4885CSNK1A1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.